Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 23, 2012

View Archived Issues

Orion discloses new androgen receptor antagonists

Novel nicotinic acetylcholine receptor ligands synthesized at CNRS and INSERM

Niacin analogue ARI-3037-MO evaluated in healthy subjects

GSK-1292263 markedly reduces lipids in nondiabetic subjects

European Institute of Oncology and University of Pisa sign oncology agreement

Dainippon Sumitomo Pharma and Shionogi to launch Aimix in Japan

Teriflunomide approved in Australia for multiple sclerosis

Votrient now available in Japan

Preclinical pharmacokinetics and efficacy of a potent MEK inhibitor presented

Novartis launches Sosei's inhalation capsule for COPD in Japan

FDA approves first cell culture-produced seasonal influenza vaccine

MedWell presents promising preclinical results for a novel drug candidate

Joyant Pharmaceuticals presents novel agents for cancer

Canadian group patents new androgen receptor ligands

FDA accepts resubmission of Levadex NDA

TRIM28 as a potential biomarker of high risk colorectal cancer

Gilead Sciences discloses novel agents for AIDS

Emory University and Wake Forest University synthesize new NET ligands

Neuren completes phase I NNZ-2566 study and files phase II IND

Study of alpha-1-antitrypsin drug shows efficacy and safety in type 1 diabetes

Basilea begins new phase I study of BAL-30072

Korean researchers patent novel agents for viral infections

Nihon Medi-Physics files for approval of NMA-78 in Japan

Cardio3 BioSciences gains clearance for phase III trial of regenerative heart failure therapy

ERYtech Pharma grants exclusive European rights for anticancer product to Orphan Europe

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
FDA greenlights Medtronic Onyx subdural hematoma treatment
BioWorld MedTech
Sometimes the darkest products (names) bring a bright spot of news to their developers, as the U.S. FDA clearance for Galway, Ireland-based Medtronic plc's Onyx...